Longeveron Inc

LGVN

Company Profile

  • Business description

    Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.

  • Contact

    1951 NW 7th Avenue
    Suite 520
    MiamiFL33136
    USA

    T: +1 305 909-0840

    https://www.longeveron.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    38

Stocks News & Analysis

stocks

ASX share undervalued despite solid growth

First-quarter performance exceeds expectations.
stocks

Chart of the Week: 3 undervalued US tech shares

Our US analysts’ top tech opportunities.
stocks

ASX payments utility looks overvalued

Australia’s invisible payments utility earns narrow moat yet valuation looks lofty.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,823.2071.40-0.80%
CAC 407,692.1377.08-0.99%
DAX 4024,830.26274.10-1.09%
Dow JONES (US)51,179.87341.41-0.66%
FTSE 10010,407.1751.33-0.49%
HKSE23,785.79344.71-1.43%
NASDAQ27,538.6961.20-0.22%
Nikkei 22569,042.11993.60-1.42%
NZX 50 Index13,691.857.810.06%
S&P 5007,801.7717.16-0.22%
S&P/ASX 2008,660.9066.80-0.77%
SSE Composite Index3,811.9030.29-0.79%

Market Movers